GrayMatters Health

September 13, 2022

GrayMatters is developing a new mental-health therapy using and targeting biomarkers of brain regions and processes associated with emotional dysregulation, rather than treating the symptoms or behaviors. Using machine learning, we fuse Electroencephalogram (EEG) and 3D fMRI (functional Magnetic Resonance Imaging) data, to create an Electrical-Fingerprint (EFP) of brain-mechanism-specific biomarkers. The Amygdala is the center of emotion regulation in the brain. Our Amygdala-EFP biomarker is used in our Prism system, which is now under clinical evaluation in five sites across the United States and Israel, to treat Post Traumatic Stress Disorder (PTSD) as an adjunct to standard of care. During treatment, patients use self-neuromodulation techniques to regulate their amygdala-EFP biomarker while interacting with an audio-visual interface. The company plans to evaluate the clinical efficacy of Prism for additional mental disorder indications like Depression, ADHD, Anxiety, and OCD.